Pinsent Masons advises in Supreme Court pharmaceutical patent case

27 Mar 2019 | 03:09 pm | 1 min. read

Today, the Supreme Court handed down its decision in 'Actavis Group PTC & Other v ICOS Corporation and others' where it unanimously ruled that the ICOS patent for a Tadalafil dosing regime was invalid.

The case related to an invalidity challenge brought by a number of generic companies in relation to a dosage regime patent protecting Eli Lilly’s blockbuster product CIALIS® (tadalafil), which is prescribed for the treatment of erectile dysfunction. 

The appeal related to the issue of obviousness of dosage regime patents, and the test to be applied. The generic companies, respondents to the appeal, successfully convinced the Supreme Court that the dosage regime patent for tadalafil was not inventive, and was therefore invalid.

On the facts of the case, the Supreme Court decided that the skilled team would have sought to implement the prior art (which disclosed the use of tadalafil in the treatment of erectile dysfunction), with the aim of ascertaining the appropriate dose. The tests to ascertain that dose were routine pre-clinical and clinical tests, including phase IIb tests to elucidate the dose-response relationship.  Accordingly, the claimed dosage regime in the patent was obvious. 

The Supreme Court took the opportunity to confirm that the judgment, like that of the Court of Appeal, does not support a general proposition that the product of well-established or routine enquiries cannot be inventive. This was a concern raised by some intervenors. The judgment is based on the specific facts of this case and involves the weighing up of several factors.

Pinsent Masons acted for a number of the successful parties in this appeal including:

  • Partner Charlotte Weekes and Senior Associate Tamsin Cornwell for Teva and Actavis Group PTC
  • Partner Christopher Sharp for the British Generic Manufacturers Association
  • Partner Catherine Drew for Medicines for Europe 

Commenting on the decision, Charlotte Weekes, Partner Pinsent Masons said, “As one of the very few pharmaceutical patent cases to have reached the Supreme Court, this unanimous decision is an important one not only to UK lawyers, but also across Europe where similar issues regarding pre-clinical and clinical trials commonly arise in pharmaceutical patent litigation. We therefore expect the judgment to have an impact on future litigation in this sector."

Latest press releases

Show me all press releases

Advising BP on first investment in AI in China

International law firm Pinsent Masons has advised global energy company BP on its investment in energy management tech specialist R&B

Pinsent Masons bolsters its Competition, EU & Trade Group with appointment of Hans Jürgen Meyer-Lindemann in Düsseldorf

Pinsent Masons continues to expand its Competition, EU & Trade Group, with the appointment of competition law specialist, Prof. Dr. Hans Jürgen Meyer-Lindemann, as a partner in the Düsseldorf office.

Pinsent Masons advises HZI on its first Energy from Waste Plant in Australia

International law firm Pinsent Masons has advised HZI on the development of the A$511 million East Rockingham Resource Recovery Facility in Western Australia

People who viewed this press release also viewed

Show me all press releases

Advising BP on first investment in AI in China

International law firm Pinsent Masons has advised global energy company BP on its investment in energy management tech specialist R&B

Pinsent Masons bolsters its Competition, EU & Trade Group with appointment of Hans Jürgen Meyer-Lindemann in Düsseldorf

Pinsent Masons continues to expand its Competition, EU & Trade Group, with the appointment of competition law specialist, Prof. Dr. Hans Jürgen Meyer-Lindemann, as a partner in the Düsseldorf office.

For all media enquiries, including arranging an interview with one of our spokespeople, please contact the press office on

+44 (0)20 7418 8199 or 

Location contacts